Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome - PubMed (original) (raw)
Clinical Trial
Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome
Nicole M Russo-Ponsaran et al. Am J Intellect Dev Disabil. 2014 Jan.
Abstract
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and the most common known genetic cause of autism. FXS is associated with psychiatric impairments, including anxiety disorders. There is a paucity of well-developed measures to characterize anxiety in FXS. However, such scales are needed to measure therapeutic responses to interventions. The Pediatric Anxiety Rating Scale-Revised (PARS-R) was evaluated in 49 individuals with FXS. Feasibility, reproducibility, and clinical validity were assessed. High inter-rater, test-retest, and cross-site reliability were achieved. PARS-R scores were correlated with parent-report and physician ratings of anxiety, suggesting good clinical validity. Results were similar within gender and age subgroups. The PARS-R is a promising tool for measuring the efficacy of interventions targeting anxiety in FXS.
Similar articles
- Convergent and discriminant validity and reliability of the pediatric anxiety rating scale in youth with autism spectrum disorders.
Storch EA, Wood JJ, Ehrenreich-May J, Jones AM, Park JM, Lewin AB, Murphy TK. Storch EA, et al. J Autism Dev Disord. 2012 Nov;42(11):2374-82. doi: 10.1007/s10803-012-1489-9. J Autism Dev Disord. 2012. PMID: 22395820 - Behavioural equivalents of anxiety in children with fragile X syndrome: parent and teacher report.
Sullivan K, Hooper S, Hatton D. Sullivan K, et al. J Intellect Disabil Res. 2007 Jan;51(Pt 1):54-65. doi: 10.1111/j.1365-2788.2006.00899.x. J Intellect Disabil Res. 2007. PMID: 17181603 - Prevalence and Predictors of Anxiety Disorders in Adolescent and Adult Males with Autism Spectrum Disorder and Fragile X Syndrome.
Ezell J, Hogan A, Fairchild A, Hills K, Klusek J, Abbeduto L, Roberts J. Ezell J, et al. J Autism Dev Disord. 2019 Mar;49(3):1131-1141. doi: 10.1007/s10803-018-3804-6. J Autism Dev Disord. 2019. PMID: 30430320 Free PMC article. - Instruments assessing anxiety in adults with intellectual disabilities: a systematic review.
Hermans H, van der Pas FH, Evenhuis HM. Hermans H, et al. Res Dev Disabil. 2011 May-Jun;32(3):861-70. doi: 10.1016/j.ridd.2011.01.034. Epub 2011 Feb 16. Res Dev Disabil. 2011. PMID: 21330101 Review. - Differential effects of anxiety and autism on social scene scanning in males with fragile X syndrome.
Crawford H, Moss J, Oliver C, Riby D. Crawford H, et al. J Neurodev Disord. 2017 Sep 25;9(1):9. doi: 10.1186/s11689-017-9189-6. J Neurodev Disord. 2017. PMID: 28946865 Free PMC article. Review.
Cited by
- Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.
Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, Kaufmann WE. Budimirovic DB, et al. J Neurodev Disord. 2017 Jun 12;9:14. doi: 10.1186/s11689-017-9193-x. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616097 Free PMC article. Review. - A Screening Tool to Measure Eye Contact Avoidance in Boys with Fragile X Syndrome.
Hall SS, Venema KM. Hall SS, et al. J Autism Dev Disord. 2017 Jul;47(7):2254-2264. doi: 10.1007/s10803-017-3139-8. J Autism Dev Disord. 2017. PMID: 28516425 Free PMC article. - Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives.
Lozano R, Thompson T, Dixon-Weber J, Erickson CA, Berry-Kravis E, Williams S, Smith E, Frazier JA, Rosselot H, Farmer C, Hessl D. Lozano R, et al. Genes (Basel). 2022 Sep 16;13(9):1660. doi: 10.3390/genes13091660. Genes (Basel). 2022. PMID: 36140827 Free PMC article. - Pharmacotherapy for Fragile X Syndrome: Progress to Date.
Davenport MH, Schaefer TL, Friedmann KJ, Fitzpatrick SE, Erickson CA. Davenport MH, et al. Drugs. 2016 Mar;76(4):431-45. doi: 10.1007/s40265-016-0542-y. Drugs. 2016. PMID: 26858239 Review. - Outcome measures for clinical trials in fragile X syndrome.
Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK; Outcome Measures Working Groups. Berry-Kravis E, et al. J Dev Behav Pediatr. 2013 Sep;34(7):508-22. doi: 10.1097/DBP.0b013e31829d1f20. J Dev Behav Pediatr. 2013. PMID: 24042082 Free PMC article.
References
- Achenbach T (1991). Manual for the child behavior checklist/4–18 & 1991 profile. Burlington, VT: University of Vermont.
- Albano AM, & Silverman WK (1996). The Anxiety Disorders Interview Schedule for Children for DSM-IV: Clinician Manual (Child and Parent Versions). San Antonio, TX: Psychological Corporation.
- Aman MG, Burrow WH, & Wolford PL (1995). The aberrant behavior checklist-community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100(3), 293–292. - PubMed
- Aman MG, Singh NN, Stewart AW, & Field CJ (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491. - PubMed
- Amaria RN, Billeisen LL, & Hagerman R (2001). Medication use in fragile X syndrome. Mental Health Aspects of Developmental Disabilities, 4(4), 143–147.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous